keyword
https://read.qxmd.com/read/37467738/potential-cost-savings-by-switching-from-subcutaneous-to-intralymphatic-insect-venom-immunotherapy
#21
JOURNAL ARTICLE
Alexandra Chabot, Claudia Lang, Thomas M Kündig, Peter Schmid-Grendelmeier, Pål Johansen
INTRODUCTION: IgE-mediated bee venom allergy can be treated with allergen-specific immunotherapy (AIT). Subcutaneous immunotherapy (SCIT) is time and cost intensive due to the repeated consultations, but the costs are justified by the high risk of potentially life-threatening allergic reactions, including anaphylaxis. However, intralymphatic immunotherapy (ILIT) offers potential to reduce treatment costs due to a significant reduction in injections and a shorter duration of therapy. Therefore, we calculated the cost savings that arise when switching from SCIT to ILIT...
July 19, 2023: International Archives of Allergy and Immunology
https://read.qxmd.com/read/37421779/intralymphatic-injection-of-chemotherapy-drugs-modulated-with-glucose-improves-their-anticancer-effect
#22
JOURNAL ARTICLE
Ariunbuyan Sukhbaatar, Shiro Mori, Kiyoto Shiga, Tetsuya Kodama
Lymph node metastasis (LNM) has a significant impact on cancer prognosis, emphasizing the need for effective treatment strategies. This study investigated the potential use of high osmotic pressure drug solutions with low viscosity administration using a lymphatic drug delivery system (LDDS) to improve LNM treatment outcomes. The hypothesis was that injection of epirubicin or nimustine at high osmotic pressure but without altered viscosity would enhance drug retention and accumulation in LNs, thereby improving the efficacy of treatment...
July 6, 2023: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/37197570/evaluation-of-intralymphatic-immunotherapy-in-allergic-rhinitis-patients-a-systematic-review-and-meta-analysis
#23
JOURNAL ARTICLE
Sijie Jiang, Shaobing Xie, Qingping Tang, Hua Zhang, Zhihai Xie, Junyi Zhang, Weihong Jiang
BACKGROUND: Intralymphatic immunotherapy (ILIT) is short-course administration of allergen-specific immunotherapy (AIT). This study is aimed at assessing the clinical efficacy and safety of ILIT in patients with allergic rhinitis (AR). METHODS: MEDLINE, PUBMED, and Cochrane Library were used to conduct electronic searches for clinical trials comparing ILIT and placebo in patients with AR. The final search took place on August 24, 2022. Cochrane Handbook for Systematic Reviews of Interventions was used to assess the risk of bias in the included studies...
2023: Mediators of Inflammation
https://read.qxmd.com/read/37186491/efficacy-of-short-term-combination-of-intralymphatic-allergen-immunotherapy-and-lokivetmab-treatment-in-canine-atopic-dermatitis-a-double-blinded-controlled-randomised-study
#24
JOURNAL ARTICLE
Kelly van Amersfort, Johannes C M Vernooij, Annette van der Lee
BACKGROUND: Allergen-specific immunotherapy (ASIT) is an effective therapy for canine atopic dermatitis (cAD). Intralymphatic immunotherapy (ILIT) is potentially beneficial in decreasing time to clinical effectiveness. OBJECTIVE: To compare clinical efficacy of six monthly ILIT injections combined with three monthly injections of lokivetmab (LVM) with monthly LVM monotherapy at Day (D)168. To monitor dogs treated with ILIT for an additional six months of subcutaneous immunotherapy (SCIT)...
April 26, 2023: Veterinary Dermatology
https://read.qxmd.com/read/37122076/allergen-immunotherapy-progress-and-future-outlook
#25
REVIEW
Lara Šošić, Marta Paolucci, Stephan Flory, Fadi Jebbawi, Thomas M Kündig, Pål Johansen
INTRODUCTION: Allergy, the immunological hypersensitivity to innocuous environmental compounds, is a global health problem. The disease triggers, allergens, are mostly proteins contained in various natural sources such as plant pollen, animal dander, dust mites, foods, fungi, and insect venoms. Allergies can manifest with a wide range of symptoms in various organs and be anything from just tedious to life-threatening. A majority of all allergy patients are self-treated with symptom-relieving medicines, while allergen immunotherapy (AIT) is the only causative treatment option...
2023: Expert Review of Clinical Immunology
https://read.qxmd.com/read/37105134/evaluation-of-safety-efficacy-and-compliance-of-intralymphatic-immunotherapy-for-allergic-rhinoconjunctivitis-a-systematic-review-and-meta-analysis
#26
Wenping Wang, Xiaoyan Wang, Hongtian Wang, Xueyan Wang
INTRODUCTION: Intralymphatic immunotherapy (ILIT) is an emerging type of allergen immunotherapy with fewer injections and shorter course for allergic rhinoconjunctivitis (ARC). The efficacy and safety have not been confirmed by informative and powerful evidence yet. METHODS: A systematic review and meta-analysis were conducted through electronic searching with PubMed, Web of Science, Embase, Scopus, and China National Knowledge Infrastructure (CNKI). The safety (incidence of adverse events [AEs]), compliance (percent of patients completing treatment), and clinical efficacy of ILIT were evaluated...
April 27, 2023: International Archives of Allergy and Immunology
https://read.qxmd.com/read/37013723/intralymphatic-immunotherapy-with-birch-and-grass-pollen-extracts-a-randomized-double-blind-placebo-controlled-clinical-trial
#27
RANDOMIZED CONTROLLED TRIAL
Lars Ahlbeck, Emelie Ahlberg, Linn Stuivers, Janne Björkander, Ulla Nyström, Pavlos Retsas, Dhanapal Govindaraj, Maria C Jenmalm, Karel Duchén
INTRODUCTION: There is a need to evaluate the safety and efficacy of intralymphatic immunotherapy (ILIT) for inducing tolerance in patients with allergic rhinitis. METHODS: Thirty-seven patients with seasonal allergic symptoms to birch and grass pollen and skin prick test >3 mm and/or IgE to birch and timothy >0.35 kU/L were randomized to either ILIT, with three doses of 0.1 mL of birch pollen and 5-grass pollen allergen extracts on aluminium hydroxide (10,000 SQ-U/ml; ALK-Abelló) or placebo using ultrasound-guided intralymphatic injections at monthly intervals...
August 2023: Clinical and Experimental Allergy
https://read.qxmd.com/read/36940185/a-systematic-review-of-allergen-immunotherapy-a-successful-therapy-for-canine-atopic-dermatitis-and-feline-atopic-skin-syndrome
#28
JOURNAL ARTICLE
Ralf S Mueller
Canine atopic dermatitis and feline atopic skin syndrome are common presentations in small animal practice. Numerous drugs are used for symptomatic therapy. The only definitive treatment based on the cause of the disease is allergen immunotherapy. Classical allergen immunotherapy (AIT) consists of subcutaneous injections of an extract containing offending allergens, with increasing doses and allergen concentrations at short intervals during the induction phase of several weeks to months followed by a maintenance phase, where a fixed dose is typically given at longer intervals...
June 1, 2023: Journal of the American Veterinary Medical Association
https://read.qxmd.com/read/36822367/x-ray-irradiation-negatively-affects-immune-responses-in-the-lymphatic-network
#29
JOURNAL ARTICLE
Sawa Kanabuchi, Narufumi Kitamura, Mayumi Takano-Kasuya, Tomoya Inose, Chihiro Nishidate, Mizuki Yamanashi, Makoto Kudo, Tatsuki Ito, Naho Ito, Hiroshi Okamoto, Yusuke Taniyama, Yoshio Kobayashi, Takashi Kamei, Kohsuke Gonda
Immune checkpoint inhibitor therapy has been attracting attention as a new cancer treatment and is likely to be widely used in combination with radiotherapy. Therefore, examination of the effects of X-ray irradiation on sentinel lymph nodes and lymphatic vessels, which are involved in antigen presentation, is important for therapy. The hindlimbs of mice were irradiated with X-rays (total radiation doses: 2, 10, and 30 Gy), and X-ray computed tomography (CT) imaging was performed using 15-nm or 2-nm gold nanoparticles (AuNPs) as contrast agents on days 7, 14, and 28 after irradiation to evaluate the diameter of the collecting lymph vessels and lymph flow within the irradiated area...
February 21, 2023: Microvascular Research
https://read.qxmd.com/read/36817467/intralymphatic-glutamic-acid-decarboxylase-administration-in-type-1-diabetes-patients-induced-a-distinctive-early-immune-response-in-patients-with-dr3dq2-haplotype
#30
JOURNAL ARTICLE
Sara Puente-Marin, Fabrícia Dietrich, Peter Achenbach, Hugo Barcenilla, Johnny Ludvigsson, Rosaura Casas
UNLABELLED: GAD-alum given into lymph nodes to Type 1 diabetes (T1D) patients participating in a multicenter, randomized, placebo-controlled double-blind study seemed to have a positive effect for patients with DR3DQ2 haplotype, who showed better preservation of C-peptide than the placebo group. Here we compared the immunomodulatory effect of GAD-alum administered into lymph nodes of patients with T1D versus placebo with focus on patients with DR3DQ2 haplotype. METHODS: GAD autoantibodies, GADA subclasses, GAD65 -induced cytokine secretion (Luminex panel) and proliferation of peripheral mononuclear cells were analyzed in T1D patients (n=109) who received either three intra-lymphatic injections (one month apart) with 4 µg GAD-alum and oral vitamin D supplementation (2000 IE daily for 120 days), or placebo...
2023: Frontiers in Immunology
https://read.qxmd.com/read/36806944/current-advances-in-house-dust-mite-allergen-immunotherapy-ait-routes-of-administration-biomarkers-and-molecular-allergen-profiling
#31
REVIEW
Thierry Batard, Walter G Canonica, Oliver Pfaar, Mohamed H Shamji, Robyn E O'Hehir, Menno C van Zelm, Laurent Mascarell
Allergy to house dust mites (HDM) is a perennial respiratory disease that affect more than half a billion people worldwide. Dermatophagoides pteronyssinus and D. farinae, two HDM species, are major sources of indoor allergens triggering allergic inflammation. Although symptomatic drugs are widely used to block the allergic reaction, allergen immunotherapy is the only curative treatment of IgE-mediated type I respiratory allergies. In this article, we review recent advances in various routes of allergen immunotherapy...
March 2023: Molecular Immunology
https://read.qxmd.com/read/36775953/papillary-intralymphatic-angioendothelioma-in-a-child-with-pik3ca-related-overgrowth-spectrum-implication-of-pi3k-pathway-in-the-vascular-tumorigenesis
#32
JOURNAL ARTICLE
Larisa Debelenko, Mahesh M Mansukhani, Fabrizio Remotti
Papillary intralymphatic angioendothelioma (PILA) is an extremely rare vascular tumor and its pathogenesis is unknown. Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-related overgrowth spectrum (PROS) is a heterogeneous group of disorders caused by mosaicism for activating mutations of PIK3CA and characterized by asymmetric overgrowth, skeletal anomalies, skin lesions, and vascular malformations. An association between PILA and PROS has not been known. We report a case of PILA involving the spleen of a young girl with the clinical and molecular diagnosis of PROS...
2023: Pediatric and Developmental Pathology
https://read.qxmd.com/read/36654485/intralymphatic-histiocytosis-like-changes-in-orofacial-granulomatosis
#33
JOURNAL ARTICLE
Aki Honda, Toshiyuki Yamamoto
This report provides rare histopathological findings of intralymphatic histiocytosis in orofacial granulomatosis involving the lower lip and unilateral upper eyelid. The number of patients with findings of intralymphatic histiocytosis in the periorbital regions is small. Here, the underlying pathogenesis of intralymphatic histiocytosis is discussed.
January 6, 2023: Clinical and Experimental Dermatology
https://read.qxmd.com/read/36530352/immunology-of-allergen-immunotherapy
#34
REVIEW
Rifat S Rahman, Duane R Wesemann
Allergen immunotherapy (AIT) is the only disease-modifying therapy for allergic disease. Through repeated inoculations of low doses of allergen-either as whole proteins or peptides-patients can achieve a homeostatic balance between inflammatory effectors induced and/or associated with allergen contact, and mediators of immunologic non-responsiveness, potentially leading to sustained clinical improvements. AIT for airborne/respiratory tract allergens and insect venoms have traditionally been supplied subcutaneously, but other routes and modalities of administration can also be effective...
2022: Immunotherapy advances
https://read.qxmd.com/read/36424528/a-randomised-double-blinded-comparison-between-subcutaneous-rush-and-intralympathic-allergen-immunotherapy-induction-in-atopic-dogs
#35
JOURNAL ARTICLE
Ralf S Mueller, Yuri Zablotski, Katja Baumann, Teresa Boehm, Bettina Kasper, Christoph Klinger, Maarten Monke, Laura Udraite-Vovk, Tamara Weitzer, Natalie K Y Gedon
BACKGROUND: Atopic dermatitis (AD) is one of the most common skin diseases in small animal practice. Allergen immunotherapy (AIT) is the only curative treatment for the disease, and oral, subcutaneous and intralymphatic administration of allergens are commonly employed. OBJECTIVES: To compare the efficacy of AIT following an induction phase with intralymphatic injections (ILIT) or rush immunotherapy (RIT). ANIMALS: Fifty privately owned dogs with AD...
November 24, 2022: Veterinary Dermatology
https://read.qxmd.com/read/36341559/a-comprehensive-overview-of-allergen-specific-immunotherapy-types-recombinant-and-natural-extract-allergens-in-the-diagnosis-and-treatment-of-allergies
#36
REVIEW
Soheila Asoudeh Moghanloo, Mohsen Forouzanfar, Mojtaba Jafarinia, Mohammad Reza Fazlollahi, Gholam Ali Kardar
Allergen-specific immunotherapy (AIT) involves administering allergen extracts. It is used to desensitize allergic patients. Herbal allergen extracts that are optimum in efficacy and fewest in side effects are still challenging to produce. To overcome these limitations, oral immunotherapy, epicutaneous immunotherapy, intralymphatic immunotherapy, and artificial recombinant allergen preparations have been evaluated. Recombinant allergens have become more popular with the development of molecular diagnostics and therapeutics...
October 26, 2022: Iranian Journal of Allergy, Asthma, and Immunology
https://read.qxmd.com/read/36316084/phase-iii-randomised-double-blind-placebo-controlled-multicentre-trial-to-evaluate-the-efficacy-and-safety-of-rhgad65-to-preserve-endogenous-beta-cell-function-in-adolescents-and-adults-with-recently-diagnosed-type-1-diabetes-carrying-the-genetic-hla-dr3-dq2
#37
JOURNAL ARTICLE
Johnny Ludvigsson, Linnea Eriksson, Christoph Nowak, Pedro F Teixeira, Martina Widman, Anton Lindqvist, Rosaura Casas, Marcus Lind, Ulf Hannelius
INTRODUCTION: Type 1 diabetes (T1D) is an autoimmune disease leading to the destruction of the insulin-producing beta cells resulting in insulin deficiency and hyperglycaemic. Today, no approved therapy exists to halt this detrimental immunologic process. In a recent phase 2b study, intralymphatic administration of recombinant human glutamic acid decarboxylase 65 kDa (rhGAD65) adsorbed to Alhydrogel adjuvant to individuals recently diagnosed with T1D and carrying the HLA DR3-DQ2 haplotype showed promising results in preserving endogenous insulin secretion, confirming the results of a large meta-analysis of three randomised placebo-controlled trials of subcutaneous rhGAD65...
October 31, 2022: BMJ Open
https://read.qxmd.com/read/36272211/establishment-of-a-protocol-for-preventive-vaccination-against-equine-insect-bite-hypersensitivity
#38
JOURNAL ARTICLE
Sara Bjork Stefansdottir, Sigridur Jonsdottir, Holmfridur Kristjansdottir, Vilhjalmur Svansson, Eliane Marti, Sigurbjorg Torsteinsdottir
Insect bite hypersensitivity (IBH) is a seasonal dermatitis of horses caused by IgE-mediated reactions to bites of Culicoides midges characterized by an imbalance of T-cell subsets. Iceland is free of the causative species but the prevalence of IBH in exported Icelandic horses is especially high. We have shown that intralymphatic (i.l.) vaccination with r-Culicoides allergens in Aluminum hydroxide (alum) and monophosphoryl lipid A (MPLA) adjuvants induces a desired Th1/regulatory T-cell response. The aim of this study was to compare i...
October 15, 2022: Veterinary Immunology and Immunopathology
https://read.qxmd.com/read/36254925/strengthening-the-case-for-intralymphatic-immunotherapy
#39
REVIEW
Hans Jürgen Hoffmann, Bjarke Hviid-Vyff
PURPOSE OF REVIEW: Intralymphatic immunotherapy (ILIT) is a promising novel method of immunotherapy, that is short and convenient, and may be very effective. Results have been varied, and efforts to unravel the real value of the treatment are ongoing. Methods used to assess the effect in clinical trials have been so varied that it is difficult to compare studies with each other. RECENT FINDINGS: Some advances have been made; the importance of injecting into the lymph node has been illustrated, and treatment with a range of medicines has proven to be successful...
December 1, 2022: Current Opinion in Allergy and Clinical Immunology
https://read.qxmd.com/read/36222329/current-and-future-treatments-for-peanut-allergy
#40
REVIEW
Tricia Lee, Sofia Edwards-Salmon, Brian P Vickery
Peanut allergy (PA) is a common, burdensome childhood disease that in most patients continues into adulthood and has historically been untreatable. However, peanut oral immunotherapy (POIT) is increasingly being incorporated into allergy practices, using both the first FDA-approved product, PTAH (previously AR101; Palforzia™, Aimmune Therapeutics), as well as store-bought peanut products. POIT in preschoolers continues to gain more acceptance as evidence accrues that it is a safe and feasible approach that may have distinct advantages...
October 12, 2022: Clinical and Experimental Allergy
keyword
keyword
50138
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.